Cancer Control (Sep 2022)

Prevalence and Patterns of EGFR Mutations in Non-small Cell Lung Cancer in the Middle East and North Africa

  • Youssra Boustany,
  • Abdelilah Laraqui,
  • Hicham El Rhaffouli,
  • Tahar Bajjou,
  • Bouchra El Mchichi,
  • Hicham El Anaz,
  • Idriss Lahlou Amine,
  • Hafsa Chahdi,
  • Mohammed Oukabli,
  • Hicham Souhi,
  • Hanane Elouazzani,
  • Ismail Abderrahmani Rhorfi,
  • Ahmed Abid,
  • Tarik Mahfoud,
  • Rachid Tanz,
  • Mohammed Ichou,
  • Khaled Ennibi,
  • Bouchra Belkadi,
  • Yassine Sekhsokh

DOI
https://doi.org/10.1177/10732748221129464
Journal volume & issue
Vol. 29

Abstract

Read online

Objectives This study aims to analyze the prevalence and spectrum of epidermal growth factor receptor (EGFR) mutations within the Middle East and North Africa region, compare the findings to other parts of the world, and explore the geographic disparities of EGFR mutations across the region. Methods We conducted a literature search using the terms “[EGFR] AND [mutation] AND [Non-Small Cell Lung Cancer] AND [Middle East OR North Africa]”, using PubMed, Science Direct, Web of science, Embase, Scopus, and Google scholar. Results A total of 15 eligible studies were included and 6122 patients with non-small cell lung cancer (NSCLC) were analyzed. Male patients were predominant in all of the considered studies, accounting for 70.4%. Of the included patients, 65.6% were smokers and 88.3% had been diagnosed with adenocarcinoma. Overall, EGFR mutations prevalence was 17.2%. In the Middle East, the reported frequency was 16.5%, ranging from 11.3% in Lebanon to 29.7% in the Gulf region. In North Africa, the prevalence of EGFR mutations was 18%, ranging from 17.5% in Egypt to 21.5% in Morocco. The most prevalent mutations were the exon 19 deletions (46.7%) followed by exon 21 substitutions (31.1%). Exon 20 alterations were detected in 10.8% of the analyzed cases, whereas exon 18 mutations were reported in 3.4% of the EGFR-mutated patients. There was 1.1% of patients that had concurrent EGFR mutations. Overall, EGFR mutation prevalence was higher in females [females vs males: 29.7% vs 5.9%, P<.001], non-smokers [non-smokers vs smokers: 31.3% vs 9.6%, P<.001], and patients with adenocarcinoma [adenocarcinoma vs non-adenocarcinoma: 18.8% vs 6.5%, P<.001]. Conclusion EGFR mutation prevalence among the Middle East and North Africa populations is slightly higher than that seen in NSCLC patients of Caucasian ethnicity but is lower than that identified in Asian NSCLC patients. The distribution of these mutations varies considerably throughout the region.